Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

Morie Gertz, Martha Lacy, John A. Lust, Philip R. Greipp, Thomas Elmer Witzig, Robert A. Kyle

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Survival of patients with plasma cell disorders has increased. However, the expanding use of melphalan in patients with longer survival suggests that myelodysplasia may become increasingly important. The objective of this study was to determine the risk of myelodysplasia after treatment with melphalan for patients with amyloidosis. We reviewed the long-term follow-up data (more than 12 years) from 101 patients with immunoglobulin light-chain amyloidosis. We identified 10 patients with myelodysplasia or acute nonlymphocytic leukemia that directly caused death for 8 and transfusion dependency for 2. Two of the 10 patients did not have development of myelodysplasia until 144 months after first exposure to alkylating agents. The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group.

Original languageEnglish (US)
Pages (from-to)1402-1406
Number of pages5
JournalHaematologica
Volume93
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

Immunoglobulin Light Chains
Melphalan
Amyloidosis
Plasma Cells
Survival
Alkylating Agents
Acute Myeloid Leukemia
Morbidity
Mortality

Keywords

  • Acute nonlymphocytic leukemia
  • Amyloidosis
  • Immunoglobulin light chain
  • Melphalan
  • Myelodysplasia

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis. / Gertz, Morie; Lacy, Martha; Lust, John A.; Greipp, Philip R.; Witzig, Thomas Elmer; Kyle, Robert A.

In: Haematologica, Vol. 93, No. 9, 09.2008, p. 1402-1406.

Research output: Contribution to journalArticle

@article{a5989440b59b4380ae11fcfb54ac2c53,
title = "Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis",
abstract = "Survival of patients with plasma cell disorders has increased. However, the expanding use of melphalan in patients with longer survival suggests that myelodysplasia may become increasingly important. The objective of this study was to determine the risk of myelodysplasia after treatment with melphalan for patients with amyloidosis. We reviewed the long-term follow-up data (more than 12 years) from 101 patients with immunoglobulin light-chain amyloidosis. We identified 10 patients with myelodysplasia or acute nonlymphocytic leukemia that directly caused death for 8 and transfusion dependency for 2. Two of the 10 patients did not have development of myelodysplasia until 144 months after first exposure to alkylating agents. The actuarial risk of myelodysplasia development at ten years was 18{\%}. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group.",
keywords = "Acute nonlymphocytic leukemia, Amyloidosis, Immunoglobulin light chain, Melphalan, Myelodysplasia",
author = "Morie Gertz and Martha Lacy and Lust, {John A.} and Greipp, {Philip R.} and Witzig, {Thomas Elmer} and Kyle, {Robert A.}",
year = "2008",
month = "9",
doi = "10.3324/haematol.12982",
language = "English (US)",
volume = "93",
pages = "1402--1406",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "9",

}

TY - JOUR

T1 - Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

AU - Gertz, Morie

AU - Lacy, Martha

AU - Lust, John A.

AU - Greipp, Philip R.

AU - Witzig, Thomas Elmer

AU - Kyle, Robert A.

PY - 2008/9

Y1 - 2008/9

N2 - Survival of patients with plasma cell disorders has increased. However, the expanding use of melphalan in patients with longer survival suggests that myelodysplasia may become increasingly important. The objective of this study was to determine the risk of myelodysplasia after treatment with melphalan for patients with amyloidosis. We reviewed the long-term follow-up data (more than 12 years) from 101 patients with immunoglobulin light-chain amyloidosis. We identified 10 patients with myelodysplasia or acute nonlymphocytic leukemia that directly caused death for 8 and transfusion dependency for 2. Two of the 10 patients did not have development of myelodysplasia until 144 months after first exposure to alkylating agents. The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group.

AB - Survival of patients with plasma cell disorders has increased. However, the expanding use of melphalan in patients with longer survival suggests that myelodysplasia may become increasingly important. The objective of this study was to determine the risk of myelodysplasia after treatment with melphalan for patients with amyloidosis. We reviewed the long-term follow-up data (more than 12 years) from 101 patients with immunoglobulin light-chain amyloidosis. We identified 10 patients with myelodysplasia or acute nonlymphocytic leukemia that directly caused death for 8 and transfusion dependency for 2. Two of the 10 patients did not have development of myelodysplasia until 144 months after first exposure to alkylating agents. The actuarial risk of myelodysplasia development at ten years was 18%. As the survival of patients with plasma cell disorders improves, myelodysplasia may be a more common cause of morbidity and mortality for this group.

KW - Acute nonlymphocytic leukemia

KW - Amyloidosis

KW - Immunoglobulin light chain

KW - Melphalan

KW - Myelodysplasia

UR - http://www.scopus.com/inward/record.url?scp=50849123758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50849123758&partnerID=8YFLogxK

U2 - 10.3324/haematol.12982

DO - 10.3324/haematol.12982

M3 - Article

VL - 93

SP - 1402

EP - 1406

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -